Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/3406| Title: | Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors | Authors: | Yip, Stephen Fleming, Adam J. Johnston, Donna L. Michaud, Jean Zelcer, Shayna Hammond, Robert Afzal, Samina Ramsay, David A. Sirachainan, Nongnuch Hongeng, Suradej Larbcharoensub, Noppadol Garami, Miklós Hauser, Péter Hortobágyi, Tibor Wilson, Beverly Hukin, Juliette Carret, Anne-Sophie Van Meter, Timothy E. Hwang, Eugene I. Gajjar, Amar Chiou, Shih-Hwa Grundy, Richard G. Nakamura, Hideo Toledano, Helen Fried, Iris Fults, Daniel Wataya, Takafumi Fryer, Chris Eisenstat, David D. Scheinemann, Katrin Lulla, Rishi R. Fangusaro, Jason R. Druker, Harriet Bartels, Ute Grant, Ronald Malkin, David McGlade, C. Jane Nicolaides, Theodore Tihan, Tarik Phillips, Joanna Majewski, Jacek Montpetit, Alexandre Bourque, Guillaume Bader, Gary D. Reddy, Alyssa T. Gillespie, G. Yancey Warmuth-Metz, Monika Rutkowski, Stefan Tabori, Uri Lupien, Mathieu Brudno, Michael Schüller, Ulrich Pietsch, Torsten Judkins, Alexander R. Hawkins, Cynthia E. Bouffet, Eric Kim, Seung-Ki Dirks, Peter B. Taylor, Michael D. Erdreich-Epstein, Anat Arrowsmith, Cheryl H. De Carvalho, Daniel D. Rutka, James T. Jabado, Nada Huang, Annie Torchia, Jonathon Golbourn, Brian Feng, Shengrui Ho, King Ching Sin-Chan, Patrick Vasiljevic, Alexandre Norman, Joseph D. Guilhamon, Paul Garzia, Livia Agamez, Natalia R. Lu, Mei Chan, Tiffany S. Picard, Daniel de Antonellis, Pasqualino Khuong-Quang, Dong-Anh Planello, Aline C. Zeller, Constanze Barsyte-Lovejoy, Dalia Lafay-Cousin, Lucie Letourneau, Louis Bourgey, Mathieu Yu, Man Gendoo, Deena M. A. Dzamba, Misko Barszczyk, Mark Medina, Tiago Riemenschneider, Alexandra N. Morrissy, A. Sorana Ra, Young-Shin Ramaswamy, Vijay Remke, Marc Dunham, Christopher P. Ng, Ho-Keung Lu, Jian-Qiang Mehta, Vivek Albrecht, Steffen Pimentel, Jose Chan, Jennifer A. Somers, Gino R. Faria, Claudia C. Roque, Lucia Fouladi, Maryam Hoffman, Lindsey M. Moore, Andrew Wang, Yin Choi, Seung Ah Hansford, Jordan R. Catchpoole, Daniel Birks, Diane K. Foreman, Nicholas K. Strother, Doug Klekner, Almos Bognár, Laszló |
Issue Date: | 2016 | Source: | 30, (6), 2016, p. 891-908 | Pages: | 891-908 | Journal: | Cancer cell | Abstract: | We recently reported that atypical teratoid rhabdoid tumors (ATRTs) comprise at least two transcriptional subtypes with different clinical outcomes; however, the mechanisms underlying therapeutic heterogeneity remained unclear. In this study, we analyzed 191 primary ATRTs and 10 ATRT cell lines to define the genomic and epigenomic landscape of ATRTs and identify subgroup-specific therapeutic targets. We found ATRTs segregated into three epigenetic subgroups with distinct genomic profiles, SMARCB1 genotypes, and chromatin landscape that correlated with differential cellular responses to a panel of signaling and epigenetic inhibitors. Significantly, we discovered that differential methylation of a PDGFRB-associated enhancer confers specific sensitivity of group 2 ATRT cells to dasatinib and nilotinib, and suggest that these are promising therapies for this highly lethal ATRT subtype. (Copyright © 2016 Elsevier Inc. All rights reserved.)Development. 2001 Nov;128(21):4217-27. (PMID: 11684658); EMBO Rep. 2002 Jul;3(7):688-94. (PMID: 12101103); Cancer Cell. 2002 Nov;2(5):415-25. (PMID: 12450796); Nat Rev Cancer. 2004 Feb;4(2):133-42. (PMID: 14964309); Neuron. 2004 Mar 25;41(6):881-90. (PMID: 15046721); J Clin Oncol. 2004 Jul 15;22(14):2877-84. (PMID: 15254056); J Clin Oncol. 2005 Mar 1;23(7):1491-9. (PMID: 15735125); Nat Rev Genet. 2006 Jan;7(1):21-33. (PMID: 16369569); N Engl J Med. 2006 Jun 15;354(24):2542-51. (PMID: 16775235); Acta Neuropathol. 2007 Aug;114(2):97-109. (PMID: 17618441); Blood. 2007 Dec 1;110(12):4055-63. (PMID: 17720881); Pediatr Blood Cancer. 2008 Jun;50(6):1198-206. (PMID: 17914733); Nat Chem Biol. 2008 Jan;4(1):33-41. (PMID: 18026094); J Clin Oncol. 2009 Jan 20;27(3):385-9. (PMID: 19064966); Clin Cancer Res. 2009 Mar 15;15(6):1923-30. (PMID: 19276269); Lab Invest. 2010 May;90(5):724-38. (PMID: 20212451); Cancer Treat Rev. 2010 Oct;36(6):492-500. (PMID: 20226597); Cancer. 2010 Nov 1;116(21):5075-81. (PMID: 20629032); Cancer Cell. 2010 Oct 19;18(4):316-28. (PMID: 20951942); Pediatr Blood Cancer. 2011 Jan;56(1):7-15. (PMID: 21108436); Clin Cancer Res. 2011 Jan 1;17(1):31-8. (PMID: 21208904); Am J Surg Pathol. 2011 Jun;35(6):933-5. (PMID: 21566516); Neuro Oncol. 2011 Dec;13(12):1296-307. (PMID: 21946044); Eur J Cancer. 2012 Feb;48(3):353-9. (PMID: 22023887); J Clin Invest. 2012 Aug;122(8):2983-8. (PMID: 22797305); Nature. 2012 Sep 6;489(7414):75-82. (PMID: 22955617); Front Oncol. 2012 Sep 12;2:114. (PMID: 22988546); Cereb Cortex. 2014 May;24(5):1361-72. (PMID: 23307637); Proc Natl Acad Sci U S A. 2013 May 7;110(19):7922-7. (PMID: 23620515); Mol Cell. 2014 Jan 23;53(2):277-89. (PMID: 24389103); Nat Med. 2014 Jul;20(7):732-40. (PMID: 24973920); Nat Neurosci. 2014 Oct;17(10):1330-9. (PMID: 25195102); Lancet Oncol. 2015 May;16(5):569-82. (PMID: 25882982); Nat Commun. 2016 Jan 28;7:10421. (PMID: 26818002); Nat Med. 2016 Feb;22(2):128-34. (PMID: 26845405); Cancer Cell. 2016 Mar 14;29(3):379-393. (PMID: 26923874); Cancer Cell. 2016 Mar 14;29(3):394-406. (PMID: 26977886); Mol Cell Biol. 1996 Jun;16(6):2802-13. (PMID: 8649389); Dev Dyn. 1997 Oct;210(2):184-90. (PMID: 9337138); Development. 1998 Mar;125(6):1005-15. (PMID: 9463347); Nature. 1998 Jul 9;394(6689):203-6. (PMID: 9671307). Linking ISSN: 15356108. Subset: MEDLINE; Grant Information: P41 GM103504 United States GM NIGMS NIH HHS; P41 HG004118 United States HG NHGRI NIH HHS; R01 GM070743 United States GM NIGMS NIH HHS; R01 HG009979 United States HG NHGRI NIH HHS Date of Electronic Publication: 20161212. ; Original Imprints: Publication: Cambridge, Mass. : Cell Press, c2002- | DOI: | 10.1016/j.ccell.2016.11.003 | Resources: | https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,athens&db=mdc&AN=27960086&site=ehost-live | Keywords: | Dasatinib/therapeutic use;Epigenesis, Genetic/drug effects;Humans;Mutation;Protein Kinase Inhibitors/pharmacology;Protein Kinase Inhibitors/therapeutic use;Pyrimidines/pharmacology;Pyrimidines/therapeutic use;Receptor, Platelet-Derived Growth Factor beta/antagonists & inhibitors;Rhabdoid Tumor/drug therapy;Teratoma/drug therapy;ATRT*;enhancer*;genomics*;rhabdoid tumors*;subgroup-specific therapeutics*;Typical Teratoid Rhabdoid Tumor;epigenomics*;Central Nervous System Neoplasms/*geneticsChromatin/*genetics;Epigenomics/*methods;Receptor, Platelet-Derived Growth Factor beta/*genetics;Rhabdoid Tumor/*genetics;SMARCB1 Protein/*genetics;Teratoma/*genetics;Cell Line, Tumor;Cell Proliferation/drug effects;Cell Survival/drug effects;Central Nervous System Neoplasms/drug therapy;DNA Methylation;Dasatinib/pharmacology | Type: | Article |
| Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.